Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00548119 · ClinicalTrials.gov registry record · Phase 2
NeoCart Phase 2 Clinical Trial
A Phase 2 study of Articular Cartilage Damage, sponsored by Histogenics Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 6
- Study locations
NCT00548119 is a Phase 2 study of Articular Cartilage Damage that has completed, run by Histogenics Corporation. The registered enrollment target is 30 participants. The trial reports 6 study locations across 5 states.
The verdict
NCT00548119, a Phase 2 study of Articular Cartilage Damage, has completed, sponsored by Histogenics Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 6
- Study locations
Study Summary
The objective of this study is to gather additional information regarding the performance of NeoCart to fill articular cartilage defects in the knee.
Conditions Studied
Interventions
- PROCEDURE microfracture
- BIOLOGICAL NeoCart
Study Locations (6)
New York
- Hospital for Special Surgery - New York
- Keller Army Community Hospital - West Point
California
- UCSF - San Francisco
Minnesota
- TRIA Orthopedic Center - Bloomington
North Carolina
- Duke Sports Medicine Center - Durham
Oregon
- OHSU - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2006-12 |
| Est. Completion | 2014-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00548119
The ClinicalTrials.gov registry entry for NCT00548119 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Histogenics Corporation, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Articular Cartilage Damage appearing as the primary indexed condition, and to 2 interventions - of which microfracture is the first listed.
NCT00548119 reports 6 study locations spanning 5 distinct geographic areas - top geographies include New York, California, Minnesota.
Frequently Asked Questions
What is clinical trial NCT00548119 about?
NCT00548119 is a clinical study titled "NeoCart Phase 2 Clinical Trial". The objective of this study is to gather additional information regarding the performance of NeoCart to fill articular cartilage defects in the knee.
What is the current status of trial NCT00548119?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2006-12. Estimated completion is 2014-03.
What conditions does trial NCT00548119 study?
This clinical trial studies the following conditions: Articular Cartilage Damage.
What interventions are being tested in trial NCT00548119?
The interventions under investigation include: microfracture (PROCEDURE), NeoCart (BIOLOGICAL).
Who is sponsoring clinical trial NCT00548119?
This trial is sponsored by Histogenics Corporation, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00548119 being conducted?
This trial has 6 study locations across California, Minnesota, New York, North Carolina, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.